ProQR Therapeutics

July 21, 2016July 21, 2016

FDA Grants Fast Track Status to Cystic Fibrosis Therapy QR-010 by ProQR

Cystic Fibrosis, News

ProQR Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its molecule QR-010 for the treatment of cystic fibrosis (CF) patients who have the deltaF508 mutation in ... Read more

June 29, 2016June 29, 2016

Phase 1 Trial Data on RNA-based Therapy for CF to Be Presented at NACFC 2016

Cystic Fibrosis, News

ProQR Therapeutics recently announced that new data from an ongoing proof-of-concept clinical study, called PQ-010-002, evaluating the effect of an RNA-based therapy (QR-010) on cystic fibrosis patients, will be presented at the North American Cystic Fibrosis Conference ... Read more

June 29, 2015November 5, 2015

ProQR Begins Enrollment For Phase 1b Study Of QR-010 In Cystic Fibrosis Patients

Cystic Fibrosis, News

ProQR Therapeutics recently announced the beginning of enrollment in the PQ-010-001 study, a global Phase 1b clinical study for the novel investigational RNA therapeutic QR-010, which is designed to repair the genetic mutation in the mRNA ... Read more

August 15, 2014November 5, 2015

New Cystic Fibrosis Biotech Company Raising Money For Breakthrough Treatment Concept

Cystic Fibrosis, News

In a summer dominated by news of Vertex Pharmaceuticals’ breakthrough cystic fibrosis combo therapy of Kalydeco with Lumacaftor proving to be effective in treating the underlying cause of the disease in ... Read more